Performance of PARI eFlow?

摘要

I refer to the article with the title "Changes in Performance of the PARI eFlow? Rapid and PARI LC Plus? during 6 Months Use by CF Patients" published in September 2009 by Rottier et al. in the Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 22, No. 3, pp. 263-269. The authors compare the aerosol performance of a to-bramycin solution (TOBI) with the PARI LC Plus jet nebulizer and the PARI eFlow? Rapid, which is a vibrating mesh nebulizer. In their study the nebulizers were assessed in vitro after they had been used for about 6 months by cystic fibrosis (CF) patients. Although the data from used LC Plus nebulizers were compared to previously published data from new LC Plus devices, the eFlow? Rapid nebulizers were characterized before and after patients used them.